Investors & Media


Altamira Therapeutics is dedicated to developing RNA-based therapeutics for extrahepatic targets. Additionally, the Company has legacy programs in allergy and viral infections, and inner ear disorders, which it intends to partner as it plans to focus exclusively on the exciting opportunities in RNA.

Latest Events

Meet Altamira: Fly exclusive interview with CEO Thomas Meyer

Read Article

Altamira Therapeutics Issues Spring 2022 Shareholder Letter

View PDF

Stock Quote


CYTO Business Update

Recent Press Releases

Investor Contact

Primary IR Contacts
U.S Tel: 800-460-0183